R1 Therapeutics raises $77.5m to progress AP306 for hyperphosphatemia
R1 Therapeutics has raised $77.5m in an oversubscribed Series A funding to advance AP306 for hyperphosphatemia in chronic kidney disease…
18 Mar 2026
FDA issues CRL to Aldeyra’s reproxalap drug application
The US Food and Drug Administration (FDA) has issued a complete response letter (CRL) to Aldeyra Therapeutics for its new drug application (NDA) of reproxalap to treat dry eye disease.…
17 Mar 2026
RFK Jr’s vaccine overhaul halted by federal judge’s ruling
US health secretary Robert F Kennedy (RFK) Jr’s ongoing overhaul of the vaccine sector in the US has hit a roadblock, after a judge halted nearly all the changes following…
17 Mar 2026
FDA accepts Sun Pharma’s Ilumya sBLA for psoriatic arthritis
The US Food and Drug Administration (FDA) has accepted for review Sun Pharmaceutical’s supplemental biologics licence application (sBLA) submitted for Ilumya (tildrakizumab-asmn) to treat adults with active psoriatic arthritis. The…
17 Mar 2026
Sentynl and PRG partner for Progerinin licence
Zydus Lifesciences subsidiary Sentynl Therapeutics has signed an agreement with Korean company PRG S&T to license Progerinin (SLC-D011), an investigational molecule intended to treat Hutchinson-Gilford Progeria Syndrome (HGPS). The move enables…
16 Mar 2026
Most London patients go private to access weight loss drugs
The majority of patients in London taking weight loss medications are doing so privately, with slow rollouts meaning only a fraction of eligible patients are accessing the drugs on the…
16 Mar 2026
GSK’s RSV jab secures FDA label expansion to larger adult population
GSK has secured a label expansion for its respiratory syncytial virus (RSV) vaccine, Arexvy, from the US Food and Drug Administration (FDA) – broadening the jab’s commercial reach on American…